|YTD NAV Return||+60.80|
|YTD Market Return||+61.32|
|Shares Outstanding||7.75 Mil|
- Last trade 12/5/2013 4:08 PM ET
|The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.|
- * Annualized returns
- Data through 12/5/2013 12:00 AM ET
|NAME||% NET ASSETS|
|Alexion Pharmaceuticals, Inc.||4.99%|
|Biogen Idec Inc||4.98%|
|Gilead Sciences Inc||4.98%|
|Regeneron Pharmaceuticals, Inc.||4.90%|
|Seattle Genetics, Inc.||2.99%|
|Cadence Pharmaceuticals, Inc.||2.95%|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.